These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
466 related articles for article (PubMed ID: 21158371)
21. Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser. Chen W; Binenbaum G; Karp K; Baumritter A; Pearson DJ; Maguire AM; Quinn GE J AAPOS; 2014 Aug; 18(4):402-4. PubMed ID: 25087645 [TBL] [Abstract][Full Text] [Related]
22. Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab. Tseng CC; Chen SN; Hwang JF; Lin CJ J Pediatr Ophthalmol Strabismus; 2012 Aug; 49 Online():e41-3. PubMed ID: 22881829 [TBL] [Abstract][Full Text] [Related]
23. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Autrata R; Krejcírová I; Senková K; Holoušová M; Doležel Z; Borek I Eur J Ophthalmol; 2012; 22(5):687-94. PubMed ID: 22669848 [TBL] [Abstract][Full Text] [Related]
24. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. Isaac M; Mireskandari K; Tehrani N J AAPOS; 2015 Apr; 19(2):140-4. PubMed ID: 25892041 [TBL] [Abstract][Full Text] [Related]
25. Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial. Mintz-Hittner HA Eur J Ophthalmol; 2012; 22(5):685-6. PubMed ID: 22669847 [TBL] [Abstract][Full Text] [Related]
26. Current and future trends in treatment of severe retinopathy of prematurity. Wallace DK; Wu KY Clin Perinatol; 2013 Jun; 40(2):297-310. PubMed ID: 23719311 [TBL] [Abstract][Full Text] [Related]
27. OUTCOMES OF NONCONFLUENT DIODE LASER PANRETINAL PHOTOCOAGULATION FOR AGGRESSIVE POSTERIOR RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB. Mammo DA; Rubino SM; Quiram PA Retina; 2021 Apr; 41(4):706-710. PubMed ID: 32796444 [TBL] [Abstract][Full Text] [Related]
28. Central retinal vein obstruction in a neonate occurring during laser photocoagulation treatment for retinopathy of prematurity. Phalak D; Rani PK; Balakrishnan D; Jalali S J Pediatr Ophthalmol Strabismus; 2014 Dec; 51 Online():e72-4. PubMed ID: 25427339 [TBL] [Abstract][Full Text] [Related]
29. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Lee JY; Chae JB; Yang SJ; Yoon YH; Kim JG Graefes Arch Clin Exp Ophthalmol; 2010 Sep; 248(9):1257-62. PubMed ID: 20393741 [TBL] [Abstract][Full Text] [Related]
30. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA; JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848 [TBL] [Abstract][Full Text] [Related]
31. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589 [TBL] [Abstract][Full Text] [Related]
32. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity. Cheng HC; Lee SM; Hsieh YT; Lin PK Retina; 2015 Apr; 35(4):660-6. PubMed ID: 25313709 [TBL] [Abstract][Full Text] [Related]
34. Spectral-domain optical coherence tomography of the macula in preterm infants treated with bevacizumab for retinopathy of prematurity. Dorta P; Kychenthal A Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):321-6. PubMed ID: 25856817 [TBL] [Abstract][Full Text] [Related]
35. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498 [TBL] [Abstract][Full Text] [Related]
36. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results]. Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449 [TBL] [Abstract][Full Text] [Related]
38. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab. Goldman DR; Baumal CR J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 24601434 [TBL] [Abstract][Full Text] [Related]
39. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921 [TBL] [Abstract][Full Text] [Related]
40. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]